Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?-Reference-Cited by-同舟云学术

Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic‐guided dosing of replacement therapy in haemophilia A?

Published:2022-05-08 Issue:4 Volume:28 Page:610-618
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Goedhart Tine M.H.J.¹,Bukkems Laura H.²,van Moort Iris³,Spence Colin C.¹,Zwaan Michel C.¹,de Maat Moniek P.M.³,Mathôt Ron A.A.²,Cnossen Marjon H.¹,

Affiliation:

1. Department of Pediatric Hematology and Oncology Erasmus MC Sophia Children's Hospital University Medical Center Rotterdam Rotterdam The Netherlands

2. Department of Clinical Pharmacology ‐ Hospital Pharmacy Amsterdam University Medical Centers Amsterdam The Netherlands

3. Department of Hematology Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14575

Reference20 articles.

1. Diagnosis and management of haemophilia

2. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia

3. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients

4. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators;Blood Reviews;2023-09